Thermo Fisher Scientific
The 10-second takeaway
For the quarter ended March 31 (Q1), Thermo Fisher Scientific beat expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue grew and GAAP earnings per share expanded significantly.
Gross margins increased, operating margins shrank, and net margins dropped.
Thermo Fisher Scientific tallied revenue of $3.10 billion. The 17 analysts polled by S&P Capital IQ predicted net sales of $2.98 billion on the same basis. GAAP reported sales were 14% higher than the prior-year quarter's $2.72 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at $1.17. The 19 earnings estimates compiled by S&P Capital IQ forecast $1.11 per share on the same basis. GAAP EPS of $0.75 for Q1 were 17% higher than the prior-year quarter's $0.64 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 43.4%, 210 basis points better than the prior-year quarter. Operating margin was 11.9%, 70 basis points worse than the prior-year quarter. Net margin was 8.9%, 40 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $3.07 billion. On the bottom line, the average EPS estimate is $1.16.
Next year's average estimate for revenue is $12.32 billion. The average EPS estimate is $4.77.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 539 members rating the stock outperform and 23 members rating it underperform. Among 169 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 166 give Thermo Fisher Scientific a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Thermo Fisher Scientific is outperform, with an average price target of $62.89.
- Add Thermo Fisher Scientific to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Motley Fool newsletter services have recommended buying shares of Thermo Fisher Scientific. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.